
MNPHARM leverages advanced genetic engineering and indoor farming to produce affordable, high-quality recombinant proteins for regenerative medicine.
Founded with a mission to revolutionize protein production, MNPHARM leverages advanced genetic engineering and controlled indoor agriculture to produce high-quality, affordable recombinant proteins. The company focuses on the regenerative medicine market, aiming to lower the costs of essential proteins for therapeutic development. Their proprietary plant-based protein expression methods ensure rapid and efficient production, catering primarily to the research community.
MNPHARM's notable achievements include the successful production of VEGF-165 and PLAP/AALP proteins, which are critical in regenerative therapies. The company has attracted significant interest from investors focused on biotech innovations. By eliminating animal components from their production process, MNPHARM not only enhances safety but also sets new standards in the industry. Their impact is marked by making cutting-edge regenerative treatments more accessible and affordable.

PhylloTech
Future Fields
futurefields.io

PlantPharm BioMed
plantpharm.biz

Juvena Therapeutics

AI Proteins
aiproteinstx.com

Transgenrx

GreenLab
greenlab.com

Recombinetics
recombinetics.com

Ventria Bioscience

Pharmatrophix
pharmatrophix.com
pH Pharma
ph-pharma.com

MBC Pharma
mbcpharma.com

Manus Bio

Phytomedics

Sunflower Therapeutics
sunflowertx.com
Companies similar to Mnpharm include PhylloTech, Future Fields, PlantPharm BioMed and Juvena Therapeutics.
Mnpharm was founded in 2015.
Mnpharm's headquarters is located in White Bear Lake, MN, US.
As of Jun 5, 2023, Mnpharm has raised a total of $400k (USD).
Mnpharm has 6 employees as of Feb 4, 2024.